BCL2 family members are subject to regulation at multiple levels, providing checks on their ability to contribute to tumorigenesis. However, findings on posttranslational BCL2 phosphorylation in different systems have been difficult to integrate. Another antiapoptotic family member, MCL1, exhibits a difference in electrophoretic mobility upon phosphorylation induced by an activator of PKC (12-O-tetradecanoylphorbol 13-acetate; TPA) versus agents that act on microtubules or protein phosphatases 1/2A. A multiple pathway model is now presented, which demonstrates that MCL1 can undergo distinct phosphorylation events -mediated through separate signaling processes and involving different target sites -in cells that remain viable in the presence of TPA versus cells destined to die upon exposure to taxol or okadaic acid. Specifically, TPA induces phosphorylation at a conserved extracellular signal-regulated kinase (ERK) site in the PEST region (Thr 163) and slows turnover of the normally rapidly degraded MCL1 protein; however, okadaic acid and taxol induce ERK-independent MCL1 phosphorylation at additional discrete sites. These findings add a new dimension to our understanding of the complex regulation of antiapoptotic BCL2 family members by demonstrating that, in addition to transcriptional and post-transcriptional regulation, MCL1 is subject to multiple, separate, post-translational phosphorylation events, produced in living versus dying cells at ERKinducible versus ERK-independent sites.
Introduction
The BCL2 family plays a central role in the control of viability in normal cells as well as in the development of cancer (Domina et al., 2000; Vrana et al., 2002) . Genes in this family are regulated through a host of transcriptional, post-transcriptional, and post-translational mechanisms (Craig, 2002) . This allows for finely tuned control of viability in normal cells, and thus provides for tissue maintenance and for regeneration, expansion, or turnover as necessary (Craig, 2002) . Expression of such viability-regulating gene products is often aberrant in cancer, as exemplified by the BCL2 overexpression seen in follicular lymphoma (Tsujimoto and Croce, 1986) . Elucidation of the various mechanisms that regulate these genes is therefore likely to suggest new strategies for promoting tumor cell death.
A variety of BCL2 family members undergo posttranslational phosphorylation, a modification that is of particular interest as it could provide an avenue for directly targeting these proteins (Ito et al., 1997; Scheid et al., 1999; Wang et al., 1999; Blagosklonny, 2001; Harada et al., 2001; Luciano et al., 2003) . Phosphorylation has been well characterized in the case of proapoptotic BAD, but is incompletely understood in the case of BCL2 itself, the prototype antiapoptotic family member. BCL2 phosphorylation is induced by an eclectic group of agents, some of which have opposing effects. On the one hand, the application of required growth factors, or activation of protein kinase C (PKC), promotes BCL2 phosphorylation in a murine myeloid cell line, NSF/N1.H7 (May et al., 1994; Ito et al., 1997; Deng et al., 2000) . On the other hand, microtubule-damaging chemotherapeutic agents, such as taxol, stimulate BCL2 phosphorylation in breast, prostate, and other cancer cells Vantieghem et al., 2002) . Protein phosphatase 1/2A inhibitors such as okadaic acid also promote BCL2 phosphorylation. While cells remain viable in the presence of growth factors and PKC activators, they undergo cell death upon exposure to microtubule-damaging agents or protein phosphatase 1/2A inhibitors. In sum, BCL2 phosphorylation is stimulated in association with the promotion of viability in some cases and cell death in others.
Studies of sites within BCL2 that are subject to phosphorylation have demonstrated the involvement of a conserved site in the upstream loop region, Ser 70. This is the case both with agents that stimulate cell growth/viability and PKC as well as with some of the above cytotoxic agents (Ito et al., 1997; Haldar et al., 1998; Srivastava et al., 1999; Yamamoto et al., 1999; Breitschopf et al., 2000) . With the latter agents, other sites have been found to be involved in some instances, notably Ser 87 and Thr 69 Haldar et al., 1998; Yamamoto et al., 1999; Breitschopf et al., 2000) . As a hypothetical model, therefore, BCL2 phosphorylation stimulated through growth factor/PKC pathways can be proposed to involve Ser 70, while that induced with microtubuledamaging or other cytotoxic agents involves this residue along with others such as Ser 87 (Blagosklonny, 2001; Ruvolo et al., 2001) . This hypothesis represents a synthesis from several systems rather than resulting from a direct comparison of the various agents within the same cell line. This could be why it does not fit certain observations, such as the taxolinduced phosphorylation at Ser 70 but not Ser 87 seen in a breast cancer cell line (Srivastava et al., 1999) , and the reduced rather than enhanced Ser 87 phosphorylation seen upon apoptosis induction with tumor necrosis factor (TNF) in endothelial cells (Dimmeler et al., 1999; Breitschopf et al., 2000) . Overall, while an increasing number of sound studies are elucidating the specifics of BCL2 phosphorylation as it occurs in a host of systems, these have been difficult to integrate into an overall model.
Diverse results have likewise been obtained in studies of the effects of the above mutations. In early studies, mutation of BCL2 Ser 70 (to a nonphosphorylatable Ala residue) was seen to result in a loss of viabilitypromoting activity in IL-3-dependent murine myeloid cells (Ito et al., 1997) . This suggested that phosphorylation of BCL2 was critical for its antiapoptotic activity. However, the same mutation was observed to result in the opposite effect in human MDA-MB231 breast cancer cells exposed to taxol (Srivastava et al., 1999) . Conversion of Ser 70 and/or Ser 87 to Ala similarly resulted in enhanced viability promotion in human Jurkat or mouse WEHI231 cells (Yamamoto et al., 1999) . These latter studies suggested that phosphorylation of BCL2 might inactivate its antiapoptotic activity. In contrast, a recent, thorough study provided convincing support for the initial findings, since mutation of Ser 70 and/or 87 to Ala was associated with a reduction in viability promotion, while mutation to phosphomimetic (Glu) residues was associated with an enhancement (Deng et al., 2004) . In addition, more pronounced effects were seen when both sites were mutated together. In this and other work, phosphorylation was also found to affect the turnover of the BCL2 protein. Thus, in the recent study, the Ser-to-Ala mutants exhibited enhanced turnover, whereas the Serto-Glu mutants exhibited slowed turnover. This agreed with an earlier observation, which was that TNFinduced dephosphorylation at Ser 87 resulted in accelerated ubiquitination and degradation of BCL2 (Dimmeler et al., 1999; Breitschopf et al., 2000) . These studies and the others above have been carried out by a variety of investigators in different systems. Thus, the extent to which differing systems contribute to these divergent results is not clear.
Our laboratory has focused on another antiapoptotic member of the BCL2 family, MCL1 (Kozopas et al., 1993; Reynolds et al., 1994 Reynolds et al., , 1996 Zhou et al., 1997 Zhou et al., , 1998 Zhou et al., , 2001 . Initial studies carried out in human myeloblastic leukemia (ML-1) cells demonstrated that TPA stimulates a rapid increase in MCL1 mRNA expression prior to the onset of monocytic differentiation (Kozopas et al., 1993; Yang et al., 1996; Townsend et al., 1998 Townsend et al., , 1999 . Microtubule-disrupting agents were also found to cause a similar increase in mRNA expression in ML-1 cells before inducing mitotic arrest and apoptotic cell death. The rapid increase in expression induced with these agents is followed by a decrease, as both the MCL1 mRNA and protein (which contains PEST sequences) are subject to rapid turnover (Yang et al., 1995 (Yang et al., , 1996 . Our recent findings demonstrate that the MCL1 protein also undergoes phosphorylation, which is stimulated by TPA (Domina et al., 2000) . In addition, microtubule-directed drugs stimulate MCL1 phosphorylation as do protein phosphatase 1/2A inhibitors, paralleling findings with BCL2. Interestingly, the latter agents differed from TPA in that MCL1 phosphorylation was associated with a band shift to reduced electrophoretic mobility, along with ensuing cell death. This suggested that, as a possibility, MCL1 might undergo differential phosphorylation with the PKC activator versus the cytotoxic agents. If this proved to be the case, it could be important for understanding the role of MCL1 phosphorylation itself and could also provide conceptual insight relevant to other antiapoptotic family members and for beginning to understand the divergence of the BCL2 findings.
The present studies directly tested the possibility that MCL1 might undergo differential phosphorylation, using TPA versus okadaic acid and taxol as prototypic inducers of different manifestations of this modification. These agents were compared in the same cell line, the Burkitt lymphoma-derived line used in previous studies (Domina et al., 2000; Vrana et al., 2002) . The results obtained show that TPA, acting in viable cells, stimulates phosphorylation at a conserved MAP kinase/ERK site in the PEST region (Thr 163) and slows the turnover of the MCL1 protein. Okadaic acid and taxol, acting in cells destined to die, stimulate phosphorylation at additional, ERK-independent sites. These findings thus demonstrate the existence of separate phosphorylation pathways that act in living versus dying cells and that target distinct sites in MCL1. This model entailing multiple, different phosphorylation events provides a blueprint for beginning to understand the differential actions of the various agents and pathways that affect the phosphorylation of antiapoptotic BCL2 family members.
Results
TPA stimulates phosphorylation at a conserved ERK-inducible site in the MCL1 PEST region and slows turnover of the MCL1 protein We focused first on further studies with TPA, since we have extensively examined the effects of this agent on MCL1 expression and phosphorylation (Kozopas et al., 1993; Yang et al., 1996; Zhou et al., 1997; Townsend et al., 1998 Townsend et al., , 1999 Domina et al., 2000) . We utilized a cell line found useful in earlier studies, the BL41-3 Burkitt lymphoma cell line in which endogenous MCL1 is amplified and abundantly expressed (Domina et al., 2000; Vrana et al., 2002) . In these cells, MCL1 phosphorylation can be monitored in the absence of the pronounced fluctuations in MCL1 expression seen in ML-1 and other cells exposed to agents such as TPA (Domina et al., 2000) . BL41-3 cells exhibit slowed growth in the presence of reduced serum, although they do not growth arrest (Vrana et al., 2002) . Therefore, to ensure that cells were proliferating under similar conditions, they were grown in medium containing 10% FBS and were fed with this medium the day before carrying out the experiments below.
MCL1 is phosphorylated at low basal levels in BL41-3 cells, and phosphorylation is dramatically increased in the presence of TPA (Domina et al., 2000) . Since the degradation of a variety of other PEST proteins is affected by phosphorylation (Rechsteiner, 1990; Clurman et al., 1996; Chen et al., 2000; Gregory and Hann, 2000; Sears et al., 2000; Koepp et al., 2001) , we wondered whether this might likewise be the case with MCL1. To examine this, we incubated BL41-3 cells in the absence or presence of a concentration of TPA known to stimulate MCL1 phosphorylation (Domina et al., 2000) , and monitored the decline in MCL1 protein expression after application of an inhibitor of protein synthesis (Li et al., 1998; Gregory and Hann, 2000; Cuconati et al., 2003) . In the absence of TPA, MCL1 exhibited rapid turnover ( Figure 1a ) as expected for a PEST protein and as seen in other cells (Yang et al., 1995) . In the presence of TPA, turnover of the protein was markedly slowed, the half-life of disappearance being extended from B2 to 4 h (Figure 1a legend) . This effect was specific as actin and tubulin were not affected by TPA, nor was BCL2 that was present at about 70% of the original level after 6 h with or without TPA ( Figure 1a and data not shown). Like TPA-induced MCL1 phosphorylation, this effect appeared dependent on PKC-induced ERK activation, since no effect was seen with an inactive phorbol derivative (4-alphaphorbol, 5 nM; data not shown) and the effect of TPA was diminished by inhibitors of either PKC (GF109203X) or ERK activation (U0126, which inhibits MEK1/2; Figure 1b ). These effects of PKC/ERK on the MCL1 protein recall the role of this pathway in increasing the expression, but not the turnover, of the MCL1 mRNA in ML-1 cells (Yang et al., 1996; Townsend et al., 1999) . Taken together, these results indicate that signaling through PKC and ERK can TPA slows turnover of the MCL1 protein and increases its phosphorylation on basally phosphorylated peptides. (a) BL41-3 cells were exposed to cycloheximide to inhibit protein synthesis and were then monitored at the indicated times for loss of the MCL1 protein (Western blotting) in the absence or presence of TPA (5 nM). a-tubulin and b-actin served as controls. The MCL1 protein is a doublet with a prominent lower component, where these two components do not represent differential phosphorylation (Domina et al., 2000) . induce MCL1 transcription as well as slow the turnover of the MCL1 protein.
TPA-induced phosphorylation of MCL1 in BL41-3 cells is not associated with a change in electrophoretic mobility (band shift) of the MCL1 protein (Domina et al., 2000) . This could mean that TPA stimulates an increase in the proportion of the protein that is phosphorylated at sites that are phosphorylated basally. Alternately, TPA might stimulate phosphorylation at additional de novo site(s) that do not result in a band shift. Two-dimensional (2D)-phosphopeptide mapping was used to examine these possibilities. Two fragments, designated phosphopeptides a and b, were seen upon thermolytic digestion of 32 P-labeled MCL1 protein from untreated BL41-3 cells (Figure 1c , upper panels). These same phosphopeptides were present in abundance in cells treated with TPA. Two faint spots (phosphopeptides a 0 and b 0 ) were present just above phosphopeptides a and b, and were also seen upon prolonged exposure (not shown) of untreated as well as TPA-treated samples. Digestion of MCL1 from untreated and TPA-treated cells with trypsin likewise yielded a similar 2D-phosphopeptide pattern ( Figure 1c , lower panels). The more complex pattern obtained here could reflect the multiple potential partial trypsin cleavage sites in MCL1 (Riviere and Tempst, 1996) and might complicate mapping. Therefore, thermolysin was used for further mapping (below). In any case, digestion with either protease showed that TPA-induced MCL1 phosphorylation occurs on peptides that are subject to this modification basally.
Previous results had also shown that the increase in MCL1 phosphorylation seen with TPA is dependent on ERK activation (Domina et al., 2000) . This suggested that ERK might act directly on MCL1 or might be a component of a cascade triggered by TPA that results in effects on MCL1. To assess the possibility of a direct effect, we carried out in vitro phosphorylation with ERK using immunoprecipitated MCL1 as substrate. Indeed, ERK was capable of phosphorylating MCL1 (Figure 2a ) and 2D mapping showed that this occurred on the same peptides seen with the endogenous MCL1 protein (Figure 2b) .
The above finding suggested that the basal and TPAinduced MCL1 phosphorylation seen endogenously in BL41-3 cells might involve proline-directed kinase phosphorylation sites (Ser or Thr residues immediately followed by Pro). Five such sites are present in human MCL1 (in bold in Figure 3 ) and one of these, Thr 163, represents a complete consensus MAP kinase phosphorylation sequence (PXT 163 P; shaded in Figure 3 ). The fact that this site is highly conserved and lies within a PEST sequence made it particularly attractive as a candidate for phosphorylation. We therefore set out to test the effect of converting this Thr to a nonphosphorylatable Ala residue. We noted that a Since similar adjacent residues in BCL2 can both undergo phosphorylation (Ser 69 and Ser 70; Yamamoto et al., 1999), we initially converted MCL1 Ser 162 and Thr 163 to Ala residues in the same construct, designated Phosphomutant 3 (wavy line above shaded region in Figure 3 ). Our rationale was that this would avoid the possibility of phosphorylation at Ser 162 confounding the interpretation of a mutation at Thr 163. For comparative purposes, we also prepared constructs containing mutations at other potential proline-directed kinase sites that are not as well conserved as Thr 163: Phosphomutants 1 and 2 contain mutations at Ser 64 and Thr 70, respectively, as well as at additional phosphorylatable residues on the same predicted thermolytic peptide ( Figure 3 ). Our goal was to assay these Phosphomutant constructs in parallel for MCL1 phosphorylation, where a loss of phosphorylation could point to sites that are normally subject to this modification. To test the above constructs, we needed a system in which transfection with exogenous MCL1 resulted in phosphorylation on the peptides that are seen with the endogenously expressed protein. 1 Potential proline-directed kinase sites in human MCL1 are in bold, the highly conserved complete consensus site in the PEST region is shaded. Ser and Thr residues that were mutated to Ala in Phosphomutants 1-3 (Pmutant 1-3) are indicated with an A above the sequence; residues mutated together in the same Phosphomutant construct are indicated with wavy lines. PEST sequences are identified as follows: Strong Potential PEST WEAK PEST INVALID PEST 2 The dog and cat sequences are shown only where they differs from human MCL1 and the rat sequence is shown only where it differs from mouse MCL1. Symbols between the sets of sequences indicate the homology between human and mouse MCL1. 3 BCL2 Homology (BH) domains are overlined and the transmembrane region (TM) is indicated with a double arrow. Differential MCL1 phosphorylation by TPA okadaic acid taxol AM Domina et al purpose, and we had previously successfully transfected these cells with MCL1 (Reynolds et al., 1994 (Reynolds et al., , 1996 . In addition, because our antibodies detect the human but not mouse or Chinese hamster MCL1 (i.e., no bands are seen on 1D Western analysis of CHO cells (Reynolds et al., 1994) ), the transfected human MCL1 gene product can be monitored without interference from endogenous Chinese hamster MCL1. We thus transiently transfected CHO cells with a wild-type MCL1 construct and carried out 2D-phosphopeptide mapping. MCL1 phosphorylation was found to occur on phosphopeptides a and b in both the absence and presence of TPA ( Figure 2c ). These phosphopeptides represented the transfected MCL1 gene product, as they were not detected in cells transfected with the pcDNA3.1 empty vector (2D electrophoresis autoradiographs were blank; not shown). In these and further mapping experiments below, the relative proportions of the phosphopeptides varied, more radioactivity being present in phosphopeptide a in some cases and the reverse being true in others (e.g., see BL41-3 cells in Figures 1 and 2c ). This relates to the fact that the phosphorylation site (identified below) was in a location susceptible to partial digestion by thermolysin. Thus, the ratio of label in phosphopeptides a and b reflected differential thermolytic digestion rather than an underlying difference in MCL1 phosphorylation within cells. The presence in CHO cells of the appropriate phosphopeptides allowed us to use this system to screen mutant constructs for changes in phosphorylation.
The above Phosphomutant constructs were transiently transfected into CHO cells to assay for expression and phosphorylation of the encoded MCL1 protein. This assay was carried out as described (Domina et al., 2000) , where 32 P-incorporation into immunoprecipitated MCL1 was assayed by autoradiography ( Figure 4a , upper photograph) and the MCL1 protein was monitored by Western blotting (Figure 4a , lower photograph). The encoded MCL1 protein was expressed with all the Phosphomutants, while the empty pcDNA 3.1 vector resulted in very low background (Figure 4a , lower photograph). 32 P-incorporation into MCL1 was robust with Phosphomutants 1 and 2, but scant with Phosphomutant 3 (Figure 4a , upper photograph). This result was striking in that the assay was initially carried out under conditions of TPA stimulation, to maximize MCL1 phosphorylation and therefore minimize the possibility of erroneously concluding that particular mutations were associated with a loss of phosphorylation. The same result was obtained upon retesting in the absence as well as the presence of TPA, although TPA did not cause an increase in phosphorylation in this system (Figure 4b and see below). It was difficult to discern from 1D electrophoresis whether a trace of 32 Pincorporation remained present with Phosphomutant 3 (Figure 4a Differential MCL1 phosphorylation by TPA okadaic acid taxol AM Domina et al was readily detectable with a construct containing a single mutation at Ser 162 (S162A; Figure 4d ) and with constructs containing mutations at other phosphorylatable residues in MCL1 (S63A, S121A, S246A mutants; not shown). As expected, thermolytic digestion of the S162A-encoded protein yielded phosphopeptides a and b upon 2D electrophoresis (data not shown). While these phosphopeptides have not been specifically identified (e.g., by sequence analysis), phosphoaminoacid analysis showed that both contained primarily phosphothreonine (data not shown), consistent with their representing overlapping phosphopeptides due to partial digestion around the Thr 163 phosphorylation site. Partial digestion is not unexpected given the sequence surrounding this site and the known specificity of thermolysin (digestion at Leu/Ile4Phe4Val, which is inhibited with Pro downstream at P 2 0 (e.g., MCL1 Leu 160; Figure 3 ) and reduced with Glu or Asp upstream at P 1 (e.g., MCL1 Leu 146 and Leu 174) (Riviere and Tempst, 1996) ). In any case, mutation of the Thr 163 conserved MAP kinase phosphorylation sequence was specifically associated with markedly reduced phosphorylation on the principal MCL1 phosphopeptides seen in untreated and TPA-treated cells.
The transient CHO cell transfection system above proved ideal for screening MCL1 for phosphorylation sites in that it demonstrated the involvement of Thr 163 and yielded results that dovetailed with those from BL41-3 cells. However, the transient expression system did not mimic the endogenously expressing system in some aspects. For example, ERK activation was detectable in CHO cells in the absence of TPA (with or without transfection) and was further increased by TPA, whereas activation changed from undetectable to abundant in untreated versus TPA-treated BL41-3 cells (Figure 5a ). This may relate to another difference noted above, which was that MCL1 phosphorylation was readily detectable in CHO cells in the absence of TPA and was not further increased in its presence (Figure 4a ). This would be compatible with the possibility that the basal ERK activity present in CHO cells might phosphorylate MCL1, and that this might occur at maximal levels with the transiently transfected gene product such that TPA produced no further increase. In this case, inhibition of ERK activation would be expected to inhibit the MCL1 phosphorylation present in untreated as well as TPA-treated CHO cells. Such a result was indeed observed, U0126 reducing MCL1 phosphorylation in either case to the trace levels seen with Phosphomutant 3 (Figure 5b and c) . This finding pointed out another difference between the two cell systems, since the low levels of basal MCL1 phosphorylation seen in BL41-3 cells did not appear to relate to ERK activation: not only was basal ERK activation not detected, but basal MCL1 phosphorylation was not blocked by U0126 (Figure 6b, lane 4) . There may thus be another (non-ERK) kinase that can carry out basal phosphorylation endogenously in BL41-3 cells. In any case, the common principle that emerges from both systems is that the ERK pathway can stimulate MCL1 phosphorylation and that this can be prevented by inhibition of this pathway ( Figure 5 and Domina et al., 2000) or by the introduction of a mutation at Thr 163 (Figure 4) .
Okadaic acid and taxol stimulate ERK-independent MCL1 phosphorylation at additional sites besides Thr 163
We next turned our attention to the MCL1 phosphorylation that occurs in the presence of okadaic acid or taxol. Previous studies had suggested that phosphorylation with these agents differs from that induced by TPA, in that it is accompanied by a band shift of the MCL1 protein, which is detectable by Western blotting using large format gels and is reversed upon digestion with phosphatase enzyme (Domina et al., 2000) . Another difference is that, whereas cells remain viable in the presence of TPA, induction of MCL1 phosphorylation with a band shift by okadaic acid or taxol is associated with G 2 /M phase and eventual cell death (Figure 6a legend and Domina et al., 2000) . The studies below were aimed at ascertaining whether the MCL1 phosphorylation/band shift induced with the latter two agents indeed Our previous studies had also suggested that ERK was not involved in the MCL1 phosphorylation seen with okadaic acid or taxol, since inhibitors of ERK activation did not block the band shift as assayed by Western blotting (Domina et al., 2000) . To follow this up, we determined whether this lack of ERK involvement (Domina et al., 2000) could be confirmed using the 32 P-incorporation assay for MCL1 phosphorylation. As an initial step in this direction, ERK activation was monitored in BL41-3 cells exposed to okadaic acid or taxol, and was found to be activated by the former but not the latter under conditions that induce the MCL1 band shift (Figure 6a and legend; Domina et al., 2000) . We then tested whether use of U0126 to inhibit ERK activation by okadaic acid would affect 32 P-incorportion into MCL1.
32 P-incorporation into MCL1 was increased upon exposure of BL41-3 cells to okadaic acid as in previous studies (Figure 6b ; Domina et al., 2000) . The MCL1 band is more diffuse and the shift much less distinct in this multiple-step assay (which involves immunoprecipitation prior to SDS-PAGE/gel transfer), as compared to the crisp shift seen upon direct Western blotting (Figure 6a ). Nonetheless, it was clear that inhibition of ERK activation with U0126 did not block the okadaic acid-induced increase in 32 P-incorporation (Figure 6b ). Overall, ERK activation did not appear critical for the MCL1 phosphorylation/band shift, since no activation occurred with taxol and inhibition of the activation produced by okadaic acid did not block its effect on MCL1.
Since okadaic acid-induced MCL1 phosphorylation did not depend on ERK activation, it would be expected to occur in the absence of the MAP kinase site at Thr 163. To test this, we transfected Phosphomutant 3 along with control constructs into CHO cells and assayed 32 Pincorporation into MCL1 in the absence and presence of okadaic acid. Phosphorylation of WT-MCL1 occurred with okadaic acid in CHO as in BL41-3 cells, although a distinct band shift was not seen with this assay as above (Figures 6c and b) . Phosphorylation with Phosphomutant 3 was barely detectable in the absence of okadaic acid (B16% of that seen with WT-MCL1 upon normalization for MCL1 protein expression, compared to values of 70-80% for Phosphomutants 1 and 2), but was readily detectable in the presence of the drug. We note that okadaic acid did not markedly affect phosphorylation of WT-MCL1 in CHO cells unlike previous observations in BL41-3 cells (increase of B2. MCL1 phosphorylation induced with okadaic acid or taxol is not dependent on ERK activation. (a) BL41-3 cells were exposed to okadaic acid (1 mM) or taxol (0.1 mM) and assayed at the indicated times for phosphorylated or total ERK (upper two panels) or for the MCL1 protein (lower panel). Cells were also exposed to TPA (10 nM for 15 min; upper two panels) or anisomycin (10 mg/ml for 1.5 or 0.75 h; lower panel, note that anisomycin was not found to increase 32 P-incorporation into MCL1). The MCL1 band shift to reduced electrophoretic mobility seen with taxol or okadaic acid reflects phosphorylation as it is reversed by treatment with phosphatase enzyme; however, the two bands of the MCL1 doublet that are present even in untreated cells (indicated by the two lines at the left of the photograph) do not represent differential phosphorylation (Domina et al., 2000) . Cells treated with okadaic acid, taxol, or TPA stopped growing: cell number at 24 h remaining at the initial inoculum value as compared to the doubling seen in untreated cells (assessed in two independent experiments with duplicates in each experiment, where the average coefficient of variation (CV) of cell number was 7.6%). However, cells treated with TPA remained 496% viable while cells treated with taxol were p30% viable (average CV ¼ 8.1%). (b) BL41-3 cells were incubated with 32 P-orthophosphoric acid for 2.75 h, with the indicated samples being exposed to U0126 (25 mM) during the final 1.75 h and/or okadaic acid (1 mM) during the final 1.5 h. Samples were assayed for 32 P-incorporation into immunoprecipitated MCL1 and total MCL1 protein, as well as for ERK activation. (c) CHO cells that had been transiently transfected with the indicated constructs were incubated with 32 P-orthophosphoric acid for 3.5 h, with the indicated samples being exposed to okadaic acid (1 mM) during the final 1.5 h. Samples were assayed for 32 P-incorporation into immunoprecipitated MCL1 (upper photograph) and total MCL1 protein (lower photograph). Relative normalized MCL1 phosphorylation was 1, 0.8, 0.7, and 0.16 for WT-MCL1, and Phosphomutants 1-3 in the absence of okadaic acid, and was 2.2, 1.6, 1, and 1.2, respectively, for these constructs in the presence of okadaic acid. This represents an okadaic acidinduced increase of 2.2, 2.1, 1.5, and 7.5 for WT-MCL1, and Phosphomutants 1-3, respectively et al., 2000), lending additional weight to the difference seen with the drug in the case of Phosphomutant 3. 32 P-incorporation into MCL1 with Phosphomutant 3 in the presence of okadaic acid was in the range of that observed with WT-MCL1 in the absence of the drug. Thus, okadaic acid-induced ERK-independent phosphorylation in this system was similar in magnitude to the ERK-dependent phosphorylation at Thr 163. This approximate equivalence was also reflected in the doubling of WT-MCL1 phosphorylation seen with okadaic acid. The fact that phosphorylation occurred in the presence of okadaic acid with a construct lacking Thr 163 suggested that other sites were involved.
To verify the involvement of other sites, we subjected the MCL1 protein from okadaic acid-treated BL41-3 cells to 2D-phosphopeptide mapping. TPA-treated cells, assayed alongside as a control, contained phosphopeptides a and b that comigrated with the phosphopeptides from untreated cells as expected (Figure 7a ). However, okadaic acid-treated cells contained additional MCL1 phosphopeptides that were not present in untreated cells and did not comigrate with phosphopeptides a and b. At least four novel phosphopeptides were present; however, it cannot be determined how many sites this represents, because of the possibility of partial digestion and/or of multisite phosphorylation on a single peptide. Taxoltreated BL41-3 cells also contained novel phosphopeptides in addition to phosphopeptides a and b, as did okadaic acid-treated CHO cells (Figure 7b ). The identity of these additional phosphopeptides remains to be explored, as does the question of the extent to which they are similar or different with the two agents and in the different systems. The present results suggest the possibility of similarities as well as differences between the two agents, as some spots exhibit similar migration patterns particularly when examined in the same 2D electrophoresis run (arrows in Figure 7 ). This recalls the fact that similarities as well as differences are seen on 1D electrophoresis, and that these agents exert their effects on MCL1 with different time courses. With okadaic acid, essentially all the MCL1 protein is shifted within 3 h (Domina et al., 2000) . In contrast, with taxol, the earliest sign of the beginning of a change is at 3 h, when only a small proportion of MCL1 is shifted (faint band at 3 h; Figure 6a ). This is followed by a progressive increase in the shifted band, which occurs in concert with the accumulation in G2/M phase, the majority of the protein being observed as shifted only after 12-24 h (Figure 6a lower panel and Domina et al., 2000) . Along with this difference in time course, okadaic acid causes a shift of both components of the MCL1 doublet while taxol ultimately results in primarily a single shifted band (Domina et al., 2000) . Overall, okadaic acid and taxol may produce some similar events, although the situation is not as simple as a single pathway induced identically by both agents. In any case, the present findings confirm that okadaic acid and taxol stimulate MCL1 phosphorylation at additional sites besides Thr 163.
The kinases as well as the sites involved in MCL1 phosphorylation with okadaic acid and taxol remain to be identified. These two agents act on different proximal targets, but have been reported to produce some similar sequellae in different systems. Among these are effects P-orthophosphoric acid for 2.5 h, with the indicated samples being exposed to okadaic acid (1 mM) for the final 1.5 h or TPA (10 mM) for the final 15 min. The MCL1 protein was immunoprecipitated and subjected to 2D-phosphopeptide mapping using thermolysin. In the panels on the right, untreated control cell samples were mixed with treated samples prior to separation of the phosphopeptides. Arrows indicate novel phosphopeptides seen with okadaic acid. (b) BL41-3 cells were incubated in the absence or presence of taxol (0.1 mM) for 11.5 h, with cells being exposed to 32 Porthophosphoric acid during the final 3 h; CHO cells that had been transiently transfected with WT-MCL1 were incubated with 32 Porthophosphoric acid for 2.5 h, and either exposed or not exposed to okadaic acid (1 mM) for 1.5 h. The MCL1 protein was immunoprecipitated and subjected to 2D-phosphopeptide mapping using thermolysin. Arrows indicate novel phosphopeptides exhibiting similar migration patterns with okadaic acid and taxol, while the asterisk indicates a distinctive phosphopeptide on stress-activated protein kinases, which are of interest because these are among the various candidate MCL1/ BCL2 kinases (Blagosklonny et al., 1997; Maundrell et al., 1997; Scatena et al., 1998; Srivastava et al., 1998; Basu et al., 2000; Fan et al., 2000; Furukawa et al., 2000; Thomas et al., 2000; Deng et al., 2001; Inoshita et al., 2002 ; but see also Du et al., 2004) . For example, exogenous overexpression of ASK-1 plus either JNK or p38 can stimulate MCL1 phosphorylation in transfected HEK293 cells (Inoshita et al., 2002) . However, examination of stress-activated protein kinases in BL41-3 cells demonstrated that the agents have opposing effects, okadaic acid but not taxol resulting in the appearance of activated forms of JNK and p38 (data not shown). Furthermore, activation was delayed until about 1 h after exposure to okadaic acid, suggesting that it occurred indirectly or with intervening molecular events. Finally, anisomycin activated stress-activated protein kinases (not shown), but did not induce MCL1 phosphorylation (Figure 6a and legend) . In sum, stress-activated protein kinase activation was not necessarily associated with MCL1 phosphorylation.
Through all of the above experiments, it became clear that the CHO cell transient expression system exhibited similarities as well as differences from the endogenously expressing BL41-3 system (e.g. MCL1 basal phosphorylation is ERK-dependent in CHO cells and TPA and band-shift inducing agents do not greatly increase phosphorylation). In an attempt to identify a system with additional similarities to MCL1 phosphorylation in BL41-3 cells for future work, we examined phosphorylation in a stably transfected cell line that we had prepared in earlier studies, FDC-P1 cells expressing WT-MCL1 (Zhou et al., 1997) . This system paralleled the endogenously expressing BL41-3 cell system in that basal MCL1 phosphorylation was present and was not dependent on ERK activation (Figure 8a ). In this experiment, MCL1 was still phosphorylated when its protein expression was induced in the presence of the MEK inhibitor, PD98059 (Figure 8a) . A further parallel was that TPA stimulated phosphorylation (although the growth factor IL-3 did not), which appeared to relate to PKC and ERK; and okadaic acid also could stimulate MCL1 phosphorylation in these cells (Figure 8b and data not shown). While the preparation and characterization of such stably transfected clones is more time intensive, initial results suggest that these cells could provide an additional opportunity to study MCL1 mutant constructs under conditions similar to those that affect phosphorylation of the endogenous protein.
Given the varied results with BCL2 in different systems, such a system with close parallels might expedite understanding of the role of phosphorylation.
Discussion
BCL2 family members are regulated at multiple levels through a host of mechanisms. In normal tissues, this serves to target the action of these viability-promoting and -inhibiting gene products to particular stages in the lifecycle of cells, controlling the flow of cells along appropriate pathways of proliferation and differentiation (Craig, 2002) . The ability to finely regulate these genes is also important for keeping in check their potential to contribute to cancer. MCL1, which was originally identified based on rapid upregulation, provides a salient example of the multiple mechanisms that can affect members of this family. MCL1 is regulated transcriptionally in response to a variety of agents and through a plethora of pathways (e.g., ERK/ SRF, PI3K/AKT, JAK/STAT) (Craig, 2002) . It is also regulated post-transcriptionally through alternative splicing (Bingle et al., 2000) . Finally, recent findings show that MCL1 is subject to post-translational phosphorylation, as are other BCL2 family members (Domina et al., 2000) . This latter modification has been extensively characterized in the case of the proapoptotic family member BAD (Scheid et al., 1999; Wang et al., 1999; Harada et al., 2001) . Similar studies on antiapoptotic BCL2 in several systems have yielded divergent results in terms of the role of this modification, and in terms of the conditions, sites, and kinases involved (reviewed in Blagosklonny, 2001; Ruvolo et al., 2001) .
Previous studies of MCL1 phosphorylation in the BL41-3 cell system revealed a difference in band shift upon induction with TPA versus microtubule-or protein phosphatase-directed agents (Domina et al., 2000) . This ability to discriminate different types of phosphorylation in the same cell line seemed likely to provide a new perspective for approaching this issue. Indeed, in the present work, TPA-induced phosphorylation in these (Zhou et al., 1997) were incubated in the absence or presence of PD98059 under standard conditions for 50 min. They were then exposed to the same concentration of PD98059 in the presence of 32 P-orthophosphoric acid (in 10% dialysed FBS and 10% WEHI conditioned medium) and to dexamethasone (0.5 mM) to induce expression of MCL1.
32
P-incorporation into immunoprecipitated MCL1 and total MCL1 protein were assayed after an additional 2 h. (b) FDC-P1 cells (clone S3) were incubated in serum-free medium for 1 h, and then exposed to 32 P-orthophosphoric acid for 1 h under serumfree/phosphate-free conditions. Cells were either left untreated or treated with TPA (20 nM). They were then assayed for 32 Pincorporation into immunoprecipitated MCL1 and total MCL1 protein at 5, 15, or 30 min. Cells exposed to IL-3 (1 mg/ml (65 nM)) instead of TPA for 15 min did not exhibit an increase in MCL1 phosphorylation (not shown) cells was found to occur at a conserved MAP kinase phosphorylation site in the MCL1 PEST region (Thr 163), while okadaic acid-and taxol-induced phosphorylation at additional other sites. With the latter two agents, phosphorylation was still present at Thr 163, suggesting that the differing phosphorylation events were not mutually exclusive. These events appeared independent, as phosphorylation in untreated and TPAtreated cells was detectable at Thr 163 but not other sites, and phosphorylation in cells exposed to okadaic acid was not blocked upon mutation of Thr 163. The recognition that multiple, independent pathways can phosphorylate discrete sites in MCL1 lends credence to the possibility that differential phosphorylation may also play a role in the case of BCL2 and might account for some of the apparent discrepancies.
MCL1 is a rapidly turned over PEST protein and ERK-inducible phosphorylation in BL41-3 cells is associated with a slowing of turnover; the half-life increasing from B2 to B4 h. MCL1 turnover remains rapid after deletion of the PEST region (which is extensive), although some change is suggested by the observations at early time points (Akgul et al., 2000) . The effect on MCL1 turnover is intriguing in view of recent findings on BCL2 phosphorylation, which show that, while BCL2 is not a rapidly turned over protein, phosphorylation results in a further prolongation of its half-life (from B10 to 417 h; Deng et al., 2004) . Alterations that affect the half-life of BCL2 also affect its antiapoptotic and antiproliferative activity (Deng et al., 2004) . However, the relationship between these effects remains to be explored in the case of BCL2 and, in the case of MCL1, it remains to be determined whether phosphorylation itself results in stabilization of the protein and/or effects on cell growth or viability. With either MCL1 or BCL2, a slowing of turnover would be expected to allow for increased expression, which could in turn enhance viability promotion (Zhou et al., 1997) . However, phosphorylation of BCL2 appears to have an effect on viability even when expression level is taken into account (Ito et al., 1997; Deng et al., 2004) . Thus, a slowing of turnover might allow for prolonged association with key target/effector molecules and/or for enhanced retention at critical intracellular locations.
Whatever the mechanism, the importance of MCL1 turnover in the control of cell viability has recently been brought to the fore by the demonstration that loss of MCL1 is an early step in apoptosis induced by DNA damage or by the viral E1A protein (Cuconati et al., 2003; Nijhawan et al., 2003) . A distinctive characteristic of MCL1 in these systems, as in differentiating cells like ML-1 cells, is its ability to act in a rapid but often shortterm fashion, under conditions of changing cell phenotype (Craig, 2002; Opferman et al., 2003) . Thus, a rapid decrease in MCL1 protein expression is a pivotal event in cells undergoing apoptosis, providing a counterpoint to the rapid increase seen in differentiating myeloid cells. It will be interesting to learn whether the decrease during apoptosis relates to, or can be affected by, phosphorylation. Increased MCL1 mRNA expression in differentiating myeloid cells has been suggested to be important for the maintenance of viability during commitment to differentiation (Craig, 2002) . Increased MCL1 phosphorylation may serve a complementary purpose, preventing the protein from being turned over before cells have passed through the 'commitment window' and initiated differentiation. We note that this might appear to be at odds with recent findings indicating that phosphorylation does not affect MCL1 turnover and may dampen its viability-promoting activity (Inoshita et al., 2002) . However, these studies used a construct containing mutations at Thr 163 plus an additional site, and thus may reflect the combined effects of more than one type of phosphorylation. Overall, while much remains to be learned, the realization that ERK-inducible MCL1 phosphorylation is distinct from other types and is associated with increased protein stability contributes to our emerging understanding of the interplay between the phosphorylation of antiapoptotic BCL2 family members, and the turnover and effects of these proteins.
Although TPA is not a physiologic agent, it acts through MAP kinase to stimulate MCL1 phosphorylation at a site that is normally phosphorylated in viable proliferating cells. Future work will be aimed at identifying and probing for a physiologic role for the MCL1 phosphorylation sites induced by okadaic acid or taxol, in particular sites that might be common. These sites could have a role in G2/M phase, since cells released from synchronization at the G1/S border exhibit a detectable band shift as they pass through G2/M, and a faint shift is likewise seen in untreated G2/ M phase-sorted cells (Domina et al., 2000) . The taxolinduced phosphorylation/band shift is closely linked to accumulation in G2/M phase and, while okadaic acid does not cause arrest in a cell cycle specific manner (Domina et al., 2000) , it is known to produce certain mitotic events (Steinmann et al., 1991) . Finally, it will be interesting to understand the pharmacologic relevance of these phosphorylation events, as the band shift occurs not only with taxol but also with microtubule disrupting agents that cause G2/M arrest, such as clinically useful vinca alkaloids (Domina et al., 2000) .
The stimulation by TPA/ERK activation of expression of the MCL1 mRNA as well as phosphorylation and stabilization of the protein (Townsend et al., 1999; Domina et al., 2000) is reminiscent of observations with cMYC, which is likewise subject to transcriptional upregulation and post-translational phosphorylation and stabilization (Sears et al., 1999; Gregory and Hann, 2000; Sears et al., 2000; Gregory et al., 2003) . Transcriptional and post-translational effects may act together to allow expression of these gene products to be increased rapidly. Overall, MCL1 may be regulated at multiple levels and in conjunction with other rapidly inducible genes such as cMYC, cFOS, and cJUN (Okazaki and Sagata, 1995; Musti et al., 1997) . Coordinated regulation of these various gene products may serve to link the control of cell viability with that of proliferation and differentiation.
As with TPA, there may be a connection between the fact that microtubule-directed agents stimulate MCL1 mRNA expression as well as MCL1 protein phosphorylation (Yang et al., 1996; Townsend et al., 1998) . This connection may be complex as, while the increase in MCL1 mRNA is induced only by microtubule-disrupting agents (Yang et al., 1996) , phosphorylation is induced by these as well as by taxol, a microtubule-stabilizing agent. Furthermore, while increased expression is closely tied to the initial disruption of the microtubule network (Townsend et al., 1998) , the MCL1 phosphorylation/band shift occurs in tandem with slower G2/M accumulation (Domina et al., 2000) . However, effects on transcription and phosphorylation may be more closely coordinated in normal cells cycling through G2/M, and this may be disturbed by drugs used to induce these effects. In conclusion, the present results, demonstrating inducerspecific sites of MCL1 phosphorylation, together with other studies on induction of the mRNA, set the stage for a more comprehensive understanding of the multiple mechanisms that regulate key viability-promoting BCL2 family members such as MCL1.
Materials and methods

Cell culture and drug treatment
The cell lines used in these experiments include the BL41-3 Burkitt lymphoma subline (Vrana et al., 2002) , in which the conditions for inducing MCL1 phosphorylation with various agents have been well established (Domina et al., 2000) , and the 5AHSMyc CHO cell line (Reynolds et al., 1994 (Reynolds et al., , 1996 , used as a readily transfectable system for testing MCL1 mutant constructs. Previously described MCL1-transfected FDC-P1 cells (FDC-P1-S3 cells, which constitutively express MCL1 under the control of the CMV promoter, and FDC-P1-7.5 cells that express MCL1 under the control of dexamethasone-inducible pMAM promoter; Zhou et al., 1997) were used for experiments with stably transfected cells. BL41-3 cells were maintained in Roswell Park Memorial Institute (RPMI) medium (Mediatech, Herndon, VA, USA) containing 10% FBS (Hyclone, Logan, UT, USA), 25 mM HEPES buffer, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (Mediatech Cellgro) and were fed with this medium on the day before performing experiments. CHO cells were maintained in Alpha Modification of Eagle's Medium (Mediatech Cellgro) containing 5% FBS, and HEPES buffer, L-glutamine and penicillin/streptomycin as above. FDC-P1 cells were maintained in medium containing FBS and WEHI/3 conditioned medium as described (Zhou et al., 1997) . TPA, okadaic acid, and taxol were purchased from Alexis Biochemicals (San Diego, CA, USA) and U0126 was from Promega (Madison, WI, USA). These drugs were made up in DMSO as in previous studies (Domina et al., 2000) .
Assay of 32 P-incorporation into MCL1
MCL1 phosphorylation was assayed as in previous studies, where 32 P-incorporation into the immunoprecipitated MCL1 protein was monitored by autoradiography and the same blot was assayed for the MCL1 protein by Western blotting (Domina et al., 2000) . Labeling of cells with 32 P-orthophosphoric acid was carried out as follows. BL41-3 cells (1-2 Â 10 7 cells for each sample) were washed twice in phosphate-free RPMI 1640 medium (GIBCO, Grand Island, NY, USA) containing 10% dialysed FBS (GIBCO) and 25 mM HEPES buffer, and were then resuspended in 1 ml of the same medium containing 32 P-orthophosphoric acid (0.4 or 1 mCi/ml; ICN, Cosa Mesa, CA, USA). CHO cells that had been transfected on the previous day (see below) were treated identically except that the concentration of dialysed FBS was 5%. FDC-P1-S3 cells, which constitutively express MCL1 under the control of the CMV promoter (Zhou et al., 1997) were incubated in serumfree medium for 1 h and then washed and incubated in serumfree/phosphate-free medium during labeling with 32 P-orthophosphoric acid. FDC-P1 cells expressing MCL1 under the control of dexamethasone-inducible pMAM promoter were incubated in phosphate-free medium containing 10% dialysed FBS and 10% WEHI/3 conditioned medium during labeling with containing 32 P-orthophosphoric acid. The total incubation period with 32 P-orthophosphoric acid was 2.5-3.5 h. Drugs were added at doses and times previously found to be optimal for the induction of MCL1 phosphorylation (Domina et al., 2000) . Thus, TPA was generally added for 15 min to 1 h, and okadaic acid for 1.5-3 h. Longer drug exposure times are required with taxol (i.e., 12-24 h). Therefore, to avoid the potential for radiolysis upon extended exposure, the drug was added in the absence of 32 P-orthophosphoric acid for 8.5 h, after which time 1 Â 10 7 cells were washed and resuspended in the presence of the same concentration of taxol along with 32 Porthophosphoric acid for an additional 3 h. After treatment with these various drugs, MCL1 was immunoprecipitated with a previously produced anti-MCL1 monoclonal antibody (Ab #31) (Zhou et al., 2001) ; this antibody was produced using bacterially derived MCL1 protein as immunogen, where the protein was made using an expression vector encoding Histagged human MCL1 lacking the carboxyl hydrophobic tail of 23 amino-acid residues. The immunoprecipitated MCL1 was then subjected to SDS-PAGE on large format gels, and transferred to PVDF membrane as previously reported (Domina et al., 2000) . The membrane was subjected to autoradiography and to Western blotting using a polyclonal antibody prepared to bacterially produced MCL1 (the immunogen contained the entire 350 amino-acid residues of the human MCL1 protein; Yang et al., 1995) . In some instances, MCL1 phosphorylation was quantitated by PhosphorImage analysis of 32 P-incorporation into immunoprecipitated MCL1. The values obtained for each sample were normalized by dividing by the corresponding value for MCL1 protein expression, assessed by densitometric scanning of the Western blots. Relative MCL1 phosphorylation in drug-treated samples or with mutant constructs was then calculated by dividing their normalized level of 32 P-incorporation into MCL1 by that observed in untreated samples expressing wild-type MCL1.
Assay of MAP kinase activation
Western blotting for activated (phosphorylated) and total ERK proteins was carried out as described previously (Domina et al., 2000) . This assay was previously found to detect more ERK2 (lower component of the ERK doublet) than ERK1 in BL41-3 cells (Domina et al., 2000) , with the phosphorylated ERK1 being more readily detectable with the phosphospecific antibody than was total ERK1 with the nonspecific antibody. While the reason for the slightly higher sensitivity of the phosphospecific antibody (compared to the nonspecific antibody) for ERK1 is not clear, this did not interfere with the use of this assay to generally assess ERK activation and its inhibition. Western blotting for phosphorylated and total JNK and p38 was carried out using antibodies from New England Biolabs (Beverly, MA, USA). The antibody detecting phosphorylated JNK is directed against Thr 183/Tyr 185 and that recognizing phosphorylated p38 is directed against Thr 180/Tyr 182.
Assay of MCL1 protein turnover
BL41-3 cells were lysed in 1 Â Laemmli buffer containing protease and phosphatase inhibitors (Sigma). The whole-cell extracts obtained were subjected to electrophoresis on either Criterion (12%; Bio-Rad) or large format polyacrylamide (15%) gels, followed by transfer to Immobilon-P (Millipore) membranes. After blocking in PBS-Tween (PBS-T) containing 3-5% nonfat dry milk, the membranes were incubated overnight at 41C with an anti-MCL1 monoclonal antibody prepared identically to Ab #31 above (Pharmingen; 1 : 2000). They were then washed three times with PBS-T, incubated with anti-mouse horseradish peroxidase (KPL; 1 : 5000), washed an additional three times with PBS-T, and subjected to enhanced chemiluminesence (Amersham). Where important for comparative purposes, membranes were reprobed with an antibody to a-tubulin (Sigma: 1 : 5000) and/or an antibody to b-actin (Sigma; 1 : 500). MCL1 turnover was assessed using standard methods (Li et al., 1998; Akgul et al., 2000; Gregory and Hann, 2000; Cuconati et al., 2003) , by exposing cells to cycloheximide to inhibit protein synthesis (25 mg/ml) and monitoring loss of the existing MCL1 protein over time by Western blotting. To estimate the half-life of decay of the MCL1 protein, the autoradiographs obtained were subjected to densitometric scanning as described previously (Townsend et al., 1998) , using autoradiographs that were not saturated.
For normalization, the values obtained at each time point for MCL1 were divided by the corresponding values for a-tubulin. The resultant MCL1/tubulin ratios were then divided by the time zero MCL1/tubulin ratio to calculate Relative MCL1. A semilog plot was prepared of Relative MCL1 versus time after cycloheximide addition, and the first order half-life of decay of MCL1 was estimated by linear regression analysis.
2D-phosphopeptide mapping
Radiolabeling with 32 P-orthophosphoric acid, immunoprecipitation of MCL1, gel electrophoresis and transfer to membrane were carried out as described above, except that protran nitrocellulose (Schleicher and Schuell, Keene, NH, USA) was used (Lutterbach and Hann, 1994) . The membrane containing the 32 P-labeled MCL1 was visualized by autoradiography, excised, washed twice with dH 2 O, incubated in 0.5% polyvinylpyrrolidone-360 (in 100 mM acetic acid) for 30 min at 371C, and then washed again with dH 2 O and suspended in 50 mM ammonium bicarbonate buffer (pH 7.6). Digestion with thermolysin or trypsin (10 mg in 100 ml ammonium bicarbonate buffer) was carried out by incubating overnight at 371C. Following the addition of 400 ml dH 2 O and centrifugation, the supernatant was dried, oxidized with performic acid, and dried again. The sample was resuspended in 4 ml of electrophoresis buffer and loaded onto a cellulose thin layer plate (0.1 mm Â 20 cm Â 20 cm). The peptides were separated by electrophoresis (1.5 kV for 30 min) in the first dimension using electrophoresis buffer consisting of 2.2% formic acid and 7.8% acetic acid (pH 1.9). They were then separated in the second dimension by ascending chromatography using phosphopeptide chromatography buffer (37.5% n-butanol, 25% pyridine, and 7.5% acetic acid). After drying, phosphopeptides were visualized by autoradiography.
In vitro phosphorylation of MCL1 by ERK Using the above-described anti-MCL1 monoclonal antibody (Ab #31) (Zhou et al., 2001) , MCL1 was immunoprecipitated from BL41-3 cells and was suspended in 1 Â MAPK buffer (New England Biolabs) containing 100 mM ATP (Sigma, St Louis, MO, USA) and 0.1 mCi/ml g-32 P ATP (ICN). The kinase reaction was performed at 301C with 0-4 U/ml ERK2 (New England Biolabs; B10 U/ng), where 1 U of ERK2 activity is defined by the supplier as the amount required to transfer 1 pmol of phosphate to myelin basic protein (100 mM) in 1 min at 301C in a total reaction volume of 30 ml. This ERK2 preparation was tested by the supplier for contamination by proteases, phosphatases, DNase, and RNase. The amount of ERK2 used here is below that used by others for in vitro phosphorylation (Deng et al., 2000; Matsuoka et al., 2002) . After 30 min, the MCL1 protein was rinsed three times with the immunoprecipitation lysis buffer, and 32 P-incorporation into MCL1 or 2D-phosphopeptide mapping was assayed as described above.
Transfection with mutant MCL1 constructs
Mutations were engineered into MCL1 using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer's instructions. Briefly, MCL1 in pBluescript (50 ng) (Zhou et al., 1997) was subjected to PCR using the upper and lower primers containing the mutated sequence (125 ng each; Table 1) in QuikChange reaction buffer (50 ml total volume) containing dNTPs and 2.5 U PFU DNA polymerase. PCR was carried out for 18 cycles (951C for 30 s, 551C for 1 min, 681C for 9 min). Methylated, unmutated plasmid was removed by digestion with the methylationdependent Dpn-1 restriction enzyme. The remaining plasmid DNA was transformed into competent DH5a cells, and colonies were selected on LB plates containing ampicillin. Colonies were amplified and plasmid was isolated (QIAprep Spin Miniprep Kit (Qiagen, Valencia, CA, USA)), followed by sequencing, carried out using the ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer, Foster City, CA, USA) at the Dartmouth College Molecular Biology Core Facility. The remainder of the MCL1 cDNA was sequenced to verify that no additional mutations were present. The mutated MCL1 cDNA was then inserted into the pcDNA 3.1 expression vector (Invitrogen, Carlsbad, CA, USA) and plasmids were prepared for transfection using the Plasmid Maxi Kit (Qiagen).
The above plasmids were transfected into CHO cells using the Effectene Transfection Reagent (Qiagen) following the manufacturer's instructions. After incubation overnight, 32 P-incorporation into MCL1 was assayed as described above.
